

**ASX Code: GSS**

26 April 2018

## **Positive trial results presented at key European conference**

- **National CPE Reference Laboratory in Ireland presented the successful results from their trial of Genetic Signatures' EasyScreen™ ESBL & CPO Detection Kit**
- **Presentation made at the major industry conference, ECCMID in Madrid**
- **Successful results highlight the strong potential for 3base™ technology to gain commercial traction in Europe**

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to announce that **Ireland's National CPE Reference Laboratory** presented the findings from its trial of the *EasyScreen™* ESBL & CPO Detection Kit at a major healthcare conference over the weekend.

The paper was presented to an audience of potential customers at the ECCMID event in Madrid. The paper, “*Evaluation of the EasyScreen™ CPO 3base real-time PCR assay for detection of carbapenemase genes directly from rectal swabs*”, was presented by the scientists leading the trial in Ireland. The trial results highlight that the automated sample extraction and the optimised *EasyScreen™* ESBL & CPO assay is promising as a sensitive and specific alternative to culture for the rapid detection of carbapenemase producing organisms. Compared to culture, which could take days, the assay can be carried out in less than 3 hours with minimal hands-on time required.

*Coordinator of the trial at the National CPE Reference Laboratory, Elaine McGrath, commented:*

*“We have been very pleased with the performance of the Genetic Signatures kit. We have conducted extensive validation on the kits which can be utilized to rapidly identify resistant organisms directly from clinical specimens. We look forward to continue working with Genetic Signatures in the future.”*

The results follow the CE-IVD registration for the sale of Genetic Signatures' *EasyScreen™* Extended Spectrum Beta-Lactamase and Carbapenemase Producing Organisms (“**ESBL & CPO**”) Detection Kit in Europe (*refer to ASX release dated 20 April 2018*). The Kit detects hospital ‘superbugs’ or ‘antibiotic resistant’ pathogens, which are a significant global concern in healthcare settings as standard treatments may be rendered ineffective.

### **Genetic Signatures CEO, Dr. John Melki commented:**

*“The positive trial results from a major European healthcare entity highlights the continued progress we are making on our European commercialisation efforts. The trial result provides potential customers confidence around the advantages of our 3base™ EasyScreen™ product suite. Our European team continues to work closely with our trial customers as well as working towards securing new trials and contracts with our expanding product suite.”*

Genetic Signatures can now sell its *EasyScreen*<sup>™</sup> ESBL & CPO Detection Kit across Europe through a hybrid of direct and distributor-led sales. Recruitment is currently underway to build GSS's direct sales team in Europe.

Carbapenemase Producing Enterobacteriaceae (CPE) was recently declared a national health emergency in Ireland, with the number of cases doubling in 2016 and increasing by a further third in 2017. Genetic Signatures' technology is well positioned to supply accurate and rapid diagnosis and help Ireland address this critical issue.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**  
**Chief Executive Officer**  
john@geneticsignatures.com  
T: +61 (0)2 9870 7580

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**<sup>™</sup>. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*<sup>™</sup> brand. Genetic Signatures' proprietary MDx **3base**<sup>™</sup> platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.